3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Vascular Diseases
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Cardiovascular Diseases
1
Blood Protein Disorders
1
Interventions
Cyclophosphamide
59
fludarabine phosphate
52
Peripheral Blood Stem Cell Transplantation
40
Busulfan
39
Tacrolimus
35
Antilymphocyte Serum
34
Mycophenolic Acid
33
Radiotherapy
30
Filgrastim
28
Cyclosporine
25
Melphalan
24
Methotrexate
22
Whole-Body Irradiation
21
fludarabine
20
Methylprednisolone
17
Etoposide
16
Cord Blood Stem Cell Transplantation
15
sargramostim
9
Rituximab
9
Granulocyte Colony-Stimulating Factor
9
Cytarabine
9
Bortezomib
9
Alemtuzumab
9
Sirolimus
8
Epoetin Alfa
7
Psychiatric Rehabilitation
6
Prednisone
6
Flow Cytometry
6
Carmustine
6
Trimethoprim, Sulfamethoxazole Drug Combination
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Plasma Cell
×
ficlatuzumab
×
Lymphoid
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled